Search results
Results from the WOW.Com Content Network
Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
Raltegravir (Isentress), developed by Merck & Co., was the first INSTI approved by the FDA in October 2007.; Elvitegravir (Vitekta), licensed by Gilead Sciences from Japan Tobacco, was approved by the U.S. Food and Drug Administration in August 2012, for use in adults starting HIV treatment for the first time as part of the fixed dose combination with emtricitabine and tenofovir disoproxil ...
Fostemsavir may cause a serious condition called immune reconstitution syndrome, similar to other approved drugs for treatment of HIV-1 infection. [8] This condition can happen at the beginning of HIV-1 treatment when the immune system may get stronger and begin to fight infections that have been hidden in the body for a long time. [8]
HIV protease inhibitors (16 P) I. Integrase inhibitors (13 P) M. Maturation inhibitors (3 P) R. Reverse transcriptase inhibitors (2 C, 8 P) Pages in category ...
It was approved by the U.S. Food and Drug Administration (FDA) on 13 March 2003 [9] as the first HIV fusion inhibitor, a new class of antiretroviral drugs. It was approved on the basis of two studies which compared the effect of optimized regimens of antiretroviral medication with and without the addition of enfuvirtide on serum viral load .
The FDA approved the drug (via the then-new FDA accelerated approval system) for use against HIV, AIDS, and AIDS Related Complex (ARC, a now-obsolete medical term for pre-AIDS illness) on March 20, 1987. [69] The time between the first demonstration that AZT was active against HIV in the laboratory and its approval was 25 months.
It was approved for PrEP against HIV infection in the United States in 2012. [17] The CDC recommends PrEP be considered for the following high-risk groups: [18] Individuals in an ongoing sexual relationship with an HIV-positive partner; Gay or bisexual men who either have had anal sex without a condom or been diagnosed with an STD in the past ...